Trump Admin Cuts Fentanyl Test Strip Funds

In a move that has experts sounding the alarm, the Trump administration has decided to end federal funding for fentanyl test strips. These small, inexpensive tools are crucial for preventing overdose deaths, and their removal from federal grant eligibility is a major shift in drug policy. Let’s dive into what this means and why it’s causing concern.

What Are Fentanyl Test Strips and Why Are They Important?

Fentanyl test strips are simple devices that allow individuals to check if illicit drugs contain fentanyl or other dangerous substances like xylazine. For just about a dollar each, these strips can provide a critical warning, giving users a chance to avoid potentially lethal doses. With overdose fatalities surging nationwide, these strips have become a vital part of harm reduction strategies.

The practice of using federal grant money to purchase and distribute these strips was first approved in 2021. Many states had already legalized the strips, recognizing their life-saving potential in the face of the ongoing opioid crisis. Supporters argue they have directly contributed to reducing overdose deaths by empowering users with information.

The Administration’s Policy Shift

However, the Substance Abuse and Mental Health Services Administration (SAMHSA) has issued a new directive. In an open letter to grant recipients, they stated that fentanyl test strips are no longer eligible for federal funding because they are “intended for use by people using drugs.” This marks a significant retreat from harm reduction strategies that had seen expansion in recent years.

While community groups and outreach programs will lose access to these funds for public distribution, federal dollars can still be used to purchase test strips for use by public health staff, law enforcement, and medical personnel. This distinction suggests a move away from direct user access towards a more controlled, professional application.

Focus on Treatment and Abstinence

The administration has been clear about its priorities, emphasizing a desire to move away from harm reduction and focus instead on treatment and abstinence-centered recovery. Officials stated that federal funding should align with “common-sense public health strategies that focus on prevention, treatment, and long-term recovery.”

Officials also described harm reduction as “an ideological concept … which has been used to advocate for policies that are incompatible with federal laws and inconsistent with this Administration’s priorities.” — Administration Officials

Instead of test strips for users, federal officials are encouraging grantees to prioritize funding for naloxone (an overdose reversal medication), sharps disposal kits, and testing or vaccination programs for infectious diseases like HIV and hepatitis. This policy shift signals a broader ideological stance on how to combat the drug crisis.